Biglycan
Biglycan[edit | edit source]
Biglycan is a small leucine-rich proteoglycan (SLRP) that is encoded by the BGN gene in humans. It is a member of the class I SLRP family and plays a crucial role in the structural integrity and function of various tissues. Biglycan is involved in the organization of the extracellular matrix (ECM) and interacts with several other matrix components and cell surface receptors.
Structure[edit | edit source]
Biglycan is characterized by a core protein that is approximately 42 kDa in size, which is decorated with glycosaminoglycan (GAG) chains, typically chondroitin sulfate or dermatan sulfate. The core protein consists of leucine-rich repeats (LRRs), which are responsible for its interactions with other proteins and molecules in the ECM.
Function[edit | edit source]
Biglycan plays a significant role in the assembly and maintenance of the ECM. It binds to collagen fibrils, influencing their organization and stability. Additionally, biglycan interacts with growth factors, such as transforming growth factor-beta (TGF-β), modulating their activity and availability.
Role in Bone and Cartilage[edit | edit source]
In bone and cartilage, biglycan is essential for normal skeletal development. It regulates the mineralization process and affects the differentiation of osteoblasts and chondrocytes. Mutations or deficiencies in biglycan can lead to skeletal dysplasias and other connective tissue disorders.
Role in Muscle[edit | edit source]
Biglycan is also expressed in muscle tissue, where it interacts with dystrophin and other components of the dystrophin-glycoprotein complex. This interaction is crucial for maintaining muscle integrity and function. Deficiencies in biglycan have been associated with muscular dystrophies.
Clinical Significance[edit | edit source]
Mutations in the BGN gene can lead to X-linked spondyloepimetaphyseal dysplasia (X-linked SEMD), a condition characterized by skeletal abnormalities. Biglycan has also been implicated in the pathogenesis of osteoarthritis and other degenerative diseases due to its role in ECM homeostasis.
Research and Therapeutic Potential[edit | edit source]
Biglycan is a subject of interest in regenerative medicine and tissue engineering. Its ability to modulate ECM components and growth factors makes it a potential target for therapies aimed at repairing or regenerating damaged tissues.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD